
Antigen Analysis: Human 4-1BB ECD Alignment
| ECD Domain | Human | Cyno | Mouse | Rabbit | 
|---|---|---|---|---|
| Human Homology | 100% | 95% | 57% | 68% | 

High positive hits screening with Beacon
Assay (SA) beads assay
 
                                        Valid Nano-well: 7560; Positive cell : 932 
                                                Positive%: 12.3%
                                        
Cell-based assay
 
                                        Valid Nano-well: 7560; Positive cell : 112 
                                                Positive%: 1.48% 
                                        

NGS sequencing

Validation of recombinant antibodies with ELISA & FACS
 31 recombinant
                                            antibodies
 31 recombinant
                                            antibodies  
  19 clones positive to 4-1BB via ELISA
 19 clones positive to 4-1BB via ELISA
                                         
  13 clones positive to human and cyno 4-1BB via FACS
 13 clones positive to human and cyno 4-1BB via FACS
                                             
  2 clones positive to human, cyno, and mouse 4-1BB via FACS
 2 clones positive to human, cyno, and mouse 4-1BB via FACS
                                            FACS, Median Fluorescence Intensity (MFI) +/-
 
                                    
Affinity analysis of 4-1BB recombinant antibodies
 
                                        KD (M) = 9.701E-08
 
                                        KD (M) = 7.069E-10
 
                     
                     
                     
                       
                     
                     
                     
                     
                     
                                
                                
                                
                                
                                
                                                      
                                                      
                                                      
                                                     
                                                     
                  											 
                             
                             
                             
                             
                             
                             
                             
                               
                               
                               
                               
                               
                               
         
         
                     
                     
                     
                     
     
             
    